Previous studies have confirmed that eIF5A2 is upregulated in various cancer types, such as gastric cancer, bladder cancer, hepatocellular carcinoma (HCC), and colon cancer [28–32]. This evidence concerns the gene EIF5A2 and urinary bladder cancer.